Clinical Trial Detail

NCT ID NCT02589717
Title An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Recruitment Approved for marketing
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Genentech, Inc.
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

urethra transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Atezolizumab

Age Groups: adult

No variant requirements are available.